<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00112723</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2011-01346</org_study_id>
    <secondary_id>NCI-2011-01346</secondary_id>
    <secondary_id>OSU-04100</secondary_id>
    <secondary_id>CDR0000429577</secondary_id>
    <secondary_id>OSU-2005C0006</secondary_id>
    <secondary_id>NCI-7002</secondary_id>
    <secondary_id>OSU 04100</secondary_id>
    <secondary_id>7002</secondary_id>
    <secondary_id>U01CA076576</secondary_id>
    <secondary_id>N01CM00070</secondary_id>
    <secondary_id>P30CA016058</secondary_id>
    <nct_id>NCT00112723</nct_id>
  </id_info>
  <brief_title>Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma</brief_title>
  <official_title>A Phase I/II Study of Flavopiridol Administered as a 30-Minute Bolus Followed by a 4-Hour Infusion in Lymphomas and Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I/II trial is studying the side effects and best dose of flavopiridol and to see&#xD;
      how well it works in treating patients with lymphoma or multiple myeloma. Drugs used in&#xD;
      chemotherapy, such as flavopiridol, work in different ways to stop the growth of cancer&#xD;
      cells, either by killing the cells or by stopping them from dividing.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the disease-specific dose-limiting toxicity and maximum tolerated dose of&#xD;
      flavopiridol in patients with relapsed or refractory lymphoma or multiple myeloma.&#xD;
&#xD;
      II. Determine the complete and partial response rate in patients with selected non-Hodgkin's&#xD;
      lymphoma (e.g., indolent B-cell, mantle cell, intermediate grade B-cell, and T/NK-cell),&#xD;
      Hodgkin's lymphoma, or multiple myeloma treated with this drug.&#xD;
&#xD;
      III. Determine the qualitative and quantitative toxic effects or this drug, in terms of organ&#xD;
      specificity, time course, predictability, and reversibility in these patients.&#xD;
&#xD;
      IV. Determine subsets of lymphoid/plasma cell malignancies that are suitable for larger phase&#xD;
      II studies designed to further evaluate the efficacy and toxicity of this drug in these&#xD;
      patients.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the pharmacokinetics of this drug in these patients. II. Determine the effect of&#xD;
      this drug on innate immunity (including T-, B-, and NK-cell subsets) and quantitative&#xD;
      immunoglobulin levels in these patients.&#xD;
&#xD;
      III. Determine whether acute infusion toxicity (e.g., fever, hypotension, tumor pain, and&#xD;
      dyspnea) observed with other flavopiridol treatment schedules is related to a&#xD;
      cytokine-release syndrome in these patients.&#xD;
&#xD;
      IV. Determine whether this drug induces response (independent of p53 mutational status) in&#xD;
      these patients.&#xD;
&#xD;
      OUTLINE: This is a phase I, dose-escalation study followed by a multicenter, phase II, pilot&#xD;
      study. Patients enrolled in the phase II portion of the study are stratified according to&#xD;
      diagnosis.&#xD;
&#xD;
      PHASE I: Patients receive flavopiridol IV over 4Â½ hours on days 1, 8, 15, and 22. Treatment&#xD;
      repeats every 6 weeks for up to 6 courses in the absence of disease progression or&#xD;
      unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of flavopiridol until&#xD;
      the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that&#xD;
      at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      PHASE II: Patients receive flavopiridol* as in phase I at the MTD determined in phase I.&#xD;
&#xD;
      NOTE: The phase II treatment dose and schedule for hairy cell leukemia patients will be&#xD;
      adapted from that developed in previous phase II studies of flavopiridol for the treatment of&#xD;
      chronic lymphocytic leukemia.&#xD;
&#xD;
      After completion of study therapy, patients are followed every 3 months for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Administratively Complete&#xD;
  </why_stopped>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-specific Dose-limiting Toxicity and Maximum Tolerated Dose of Flavopiridol Graded According to the CTCAE (Common Toxicity Criteria for Adverse Effects) Version 4.0 (Phase I)</measure>
    <time_frame>28 days</time_frame>
    <description>Dose limiting toxicity (DLT) for an individual disease group is defined as 1) any grade 3-4 non-hematologic toxicity (except leukopenia or neutropenia) that does not resolve or decrease to grade 1-2 within 2 weeks, or 2) any grade 4 hematologic toxicity that causes more than a 1 week delay in administration of therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>28 days</time_frame>
    <description>The maximum tolerated dose (MTD) is defined as that dose level beneath the dose at which 2 or more of 6 patients experience DLT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete and Partial Response Rate (Phase II)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Patients were assessed for clinical response after two , four and six cycle with laboratory studies, physical exam, and CT scans. Response was evaluated using the modified NCI-sponsored Working Group Lymphoma Response Criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Qualitative and Quantitative Toxicities in Regard to Organ Specificity</measure>
    <time_frame>Up to 30 days after completion of study treatment</time_frame>
    <description>The NCI Common Toxicity Criteria for Adverse Events (version 3.0) were used to define and grade toxicity for patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lymphoid/Plasma Cell Malignancies</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Identify subsets, based on levels of response (PR and SD), of lymphoid / plasma cell malignancies that are suitable for larger phase II studies designed to further evaluate the efficacy and toxicity of flavopiridol.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Area Under the Curve; AUC) of Flavopiridol</measure>
    <time_frame>0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours post-dose on Days 1 and 22 of Cycle 1</time_frame>
    <description>Whole blood samples were collected for pharmacokinetics analysis during the first (Day 1) and fourth (Day 22) treatments during cycle 1. Samples were collected on both occasions prior to dosing and at 0.5, 1, 3, 4.5, 6, 8 and 24 hour after the start of the bolus infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Reporting Acute Infusion Toxicity (e.g., Fever, Hypotension, Tumor Pain, and Dyspnea)</measure>
    <time_frame>Up to 30 days after completion of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induced Response in Patients Independent of p53 Mutational Status</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Effects of Flavopiridol on Normal Peripheral Blood Mononuclear Cells (PBMCs).</measure>
    <time_frame>Day 1</time_frame>
    <description>The correlation of the pharmacodynamic effects of flavopiridol on normal peripheral blood mononuclear cells (PBMCs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Cmax) of Flavopiridol</measure>
    <time_frame>0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours post-dose on Days 1 and 22 of Cycle 1</time_frame>
    <description>Whole blood samples were collected for pharmacokinetics analysis during the first (Day 1) and fourth (Day 22) treatments during cycle 1. Samples were collected on both occasions prior to dosing and at 0.5, 1, 3, 4.5, 6, 8 and 24 hour after the start of the bolus infusion.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Adult Lymphocyte Depletion Hodgkin Lymphoma</condition>
  <condition>Adult Lymphocyte Predominant Hodgkin Lymphoma</condition>
  <condition>Adult Mixed Cellularity Hodgkin Lymphoma</condition>
  <condition>Adult Nodular Sclerosis Hodgkin Lymphoma</condition>
  <condition>Anaplastic Large Cell Lymphoma</condition>
  <condition>Angioimmunoblastic T-cell Lymphoma</condition>
  <condition>Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue</condition>
  <condition>Nodal Marginal Zone B-cell Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Mixed Cell Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Small Cleaved Cell Lymphoma</condition>
  <condition>Recurrent Adult Grade III Lymphomatoid Granulomatosis</condition>
  <condition>Recurrent Adult Hodgkin Lymphoma</condition>
  <condition>Recurrent Adult T-cell Leukemia/Lymphoma</condition>
  <condition>Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma</condition>
  <condition>Recurrent Grade 1 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 2 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 3 Follicular Lymphoma</condition>
  <condition>Recurrent Mantle Cell Lymphoma</condition>
  <condition>Recurrent Marginal Zone Lymphoma</condition>
  <condition>Recurrent Mycosis Fungoides/Sezary Syndrome</condition>
  <condition>Recurrent Small Lymphocytic Lymphoma</condition>
  <condition>Refractory Multiple Myeloma</condition>
  <condition>Splenic Marginal Zone Lymphoma</condition>
  <condition>Stage I Multiple Myeloma</condition>
  <condition>Stage II Multiple Myeloma</condition>
  <condition>Stage III Multiple Myeloma</condition>
  <condition>WaldenstrÃ¶m Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>Treatment (alvocidib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PHASE I: Patients receive flavopiridol IV over 4Â½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of flavopiridol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
PHASE II: Patients receive flavopiridol* as in phase I at the MTD determined in phase I.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alvocidib</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (alvocidib)</arm_group_label>
    <other_name>FLAVO</other_name>
    <other_name>flavopiridol</other_name>
    <other_name>HMR 1275</other_name>
    <other_name>L-868275</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of 1 of the following hematologic malignancies:&#xD;
&#xD;
               -  Hodgkin's lymphoma&#xD;
&#xD;
               -  Non-Hodgkin's lymphoma (NHL)&#xD;
&#xD;
               -  Multiple myeloma&#xD;
&#xD;
          -  Patients in the phase II portion of the study are enrolled in 1 of the following&#xD;
             strata according to diagnosis*&#xD;
&#xD;
               -  Stratum 1: Indolent B-cell NHL (non-Hodgkin's lymphoma), follicle center B-cell&#xD;
                  NHL (grade 1, 2, or 3), marginal zone lymphoma, Waldenstrom's macroglobulinemia,&#xD;
                  or small lymphocytic lymphoma (without blood lymphocytosis at any point in the&#xD;
                  disease process)&#xD;
&#xD;
                    -  Must have progressive lymphadenopathy, worsening cytopenias, or progressive&#xD;
                       symptoms attributed to lymphoma&#xD;
&#xD;
                    -  Must require therapy, as determined by progressive anemia, thrombocytopenia,&#xD;
                       symptoms (e.g., fever, night sweats, weight loss, or fatigue), or&#xD;
                       progressive lymphadenopathy that causes discomfort&#xD;
&#xD;
                    -  Received â¥ 2 prior therapies, including rituximab&#xD;
&#xD;
               -  Stratum 1a: Hairy cell leukemia&#xD;
&#xD;
                    -  Must require therapy, as determined by progressive cytopenias or symptoms&#xD;
                       (fever, night sweats, weight loss, or fatigue)&#xD;
&#xD;
                    -  Must have received â¥ 2 therapies&#xD;
&#xD;
               -  Stratum 2: Mantle cell lymphoma, as determined by the presence of cyclin D1&#xD;
                  staining OR t(11;14)&#xD;
&#xD;
               -  Stratum 3: Intermediate grade B-cell NHL, including diffuse large B-cell NHL and&#xD;
                  T-cell rich B-cell NHL&#xD;
&#xD;
                    -  Diffuse large B-cell NHL arising from an indolent NHL (i.e., transformed&#xD;
                       lymphoma) allowed&#xD;
&#xD;
                    -  Ineligible for potentially curative autologous stem cell transplantation&#xD;
&#xD;
               -  Stratum 4: T-cell and natural killer-cell NHL, including anaplastic large cell&#xD;
                  lymphoma and peripheral T-cell NHL&#xD;
&#xD;
                    -  Primary cutaneous lymphoma or Sezary syndrome allowed provided criteria for&#xD;
                       measurable disease are met&#xD;
&#xD;
                    -  Received â¥ 1 prior systemic therapy&#xD;
&#xD;
               -  Stratum 5: Hodgkin's lymphoma&#xD;
&#xD;
                    -  Any of the following subtypes are allowed:&#xD;
&#xD;
                         -  Nodular sclerosing&#xD;
&#xD;
                         -  Mixed cellularity&#xD;
&#xD;
                         -  Lymphocyte predominant&#xD;
&#xD;
                         -  Lymphocyte depleted&#xD;
&#xD;
                    -  Ineligible for potentially curative autologous stem cell transplantation&#xD;
&#xD;
               -  Stratum 6: Progressive stage I or stage II or IIIA multiple myeloma meeting â¥ 1&#xD;
                  major and 1 minor criterion OR â¥ 3 minor criteria as follows:&#xD;
&#xD;
                    -  Major criteria&#xD;
&#xD;
                         -  Plasmacytoma on tissue biopsy&#xD;
&#xD;
                         -  Bone marrow plasmacytosis â¥ 30% of marrow cellularity&#xD;
&#xD;
                         -  Monoclonal paraprotein â¥ 3,500 mg/dL (IgG), or â¥ 2,000 mg/dL (IgA), OR&#xD;
                            monoclonal protein (Bence-Jones protein) â¥ 1,000 mg by 24-hour urine&#xD;
                            collection&#xD;
&#xD;
                    -  Minor criteria&#xD;
&#xD;
                         -  Bone marrow plasmacytosis 10-29% of marrow cellularity&#xD;
&#xD;
                         -  Monoclonal paraprotein &lt; 3,500 mg/dL (IgG) or &lt; 2,000 mg/dL (IgA)&#xD;
&#xD;
                         -  Lytic bone lesions by x-ray or CT scan&#xD;
&#xD;
                         -  Decrease in normal IgM (&lt; 50 mg/dL), IgA (&lt; 100 mg/dL), or IgG (&lt; 600&#xD;
                            mg/dL)&#xD;
&#xD;
          -  Relapsed or refractory disease&#xD;
&#xD;
          -  Measurable disease, defined by 1 of the following:&#xD;
&#xD;
               -  At least 1 node &gt; 2 cm by CT scan&#xD;
&#xD;
               -  Measurable disease in a lymphoid structure (i.e., spleen) by CT scan&#xD;
&#xD;
               -  Bone marrow involvement (&gt; 20% of marrow cellularity)&#xD;
&#xD;
               -  Patients with multiple myeloma must have detectable serum or urinary paraprotein&#xD;
&#xD;
               -  Patients with only cutaneous or subcutaneous disease (i.e., no measurable lymph&#xD;
                  node or bone marrow disease) are eligible if the extent of rash or skin&#xD;
                  involvement OR the size of the nodules are measurable&#xD;
&#xD;
          -  Must have received â¥ 1 prior therapy&#xD;
&#xD;
               -  Steroids alone are not considered prior therapy for patients with NHL or&#xD;
                  Hodgkin's lymphoma&#xD;
&#xD;
               -  High-dose dexamethasone is considered 1 prior therapy for patients with multiple&#xD;
                  myeloma&#xD;
&#xD;
          -  No standard effective therapy exists&#xD;
&#xD;
          -  No HIV-associated lymphoma&#xD;
&#xD;
          -  No nonsecretory multiple myeloma&#xD;
&#xD;
          -  Performance status - ECOG (Eastern Cooperative Oncology Group) 0-2&#xD;
&#xD;
          -  No concurrent hormonal therapy except steroids for new adrenal failure or hormones&#xD;
             administered for non-disease-related conditions (e.g., insulin for diabetes)&#xD;
&#xD;
          -  Hemoglobin â¥ 9.0 g/dL*&#xD;
&#xD;
          -  Absolute neutrophil count â¥ 1,500/mm^3*&#xD;
&#xD;
          -  Platelet count â¥ 50,000/mm^3*&#xD;
&#xD;
          -  AST (aspartate aminotransferase) â¤ 3 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin â¤ 2 times ULN&#xD;
&#xD;
          -  No major renal dysfunction that would preclude study compliance or participation&#xD;
&#xD;
          -  Phase I:&#xD;
&#xD;
               -  Creatinine â¤ 1.5 mg/dL&#xD;
&#xD;
               -  Creatinine clearance â¥ 70 mL/min&#xD;
&#xD;
          -  Phase II:&#xD;
&#xD;
               -  Creatinine â¤ 2.0 mg/dL&#xD;
&#xD;
               -  Creatinine clearance â¥ 50 mL/min&#xD;
&#xD;
          -  No cardiac or vascular dysfunction that would preclude central venous access, vigorous&#xD;
             hydration, or hemodialysis&#xD;
&#xD;
          -  No other major cardiac dysfunction that would preclude study compliance or&#xD;
             participation&#xD;
&#xD;
          -  No major pulmonary dysfunction that would preclude study compliance or participation&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No chronic gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or&#xD;
             short gut syndrome) that would preclude study compliance or participation&#xD;
&#xD;
          -  No other major organ system (including neurological or psychiatric) dysfunction that&#xD;
             would preclude study compliance or participation&#xD;
&#xD;
          -  Prior radiotherapy, including radioimmunotherapy, allowed&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
          -  Prior idiotype vaccination or stem cell transplantation allowed&#xD;
&#xD;
          -  More than 6 weeks since prior mitomycin or nitrosoureas&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
          -  More than 4 weeks since other prior therapy&#xD;
&#xD;
          -  Prior systemic steroids allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Jones</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>June 2, 2005</study_first_submitted>
  <study_first_submitted_qc>June 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2005</study_first_posted>
  <results_first_submitted>March 23, 2015</results_first_submitted>
  <results_first_submitted_qc>June 27, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 8, 2016</results_first_posted>
  <last_update_submitted>June 27, 2016</last_update_submitted>
  <last_update_submitted_qc>June 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Mycosis Fungoides</mesh_term>
    <mesh_term>Sezary Syndrome</mesh_term>
    <mesh_term>Leukemia, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
    <mesh_term>Leukemia-Lymphoma, Adult T-Cell</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
    <mesh_term>Lymphomatoid Granulomatosis</mesh_term>
    <mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alvocidib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were accrued to the study between April 2006 and September 2010.</recruitment_details>
      <pre_assignment_details>Patients with confirmed diagnosis of NHL (Non-Hodgkin's lymphoma) were accrued to one of the four cohorts defined by the World Health Organization criteria: indolent B-cell, mantle cell, intermediate-grade B-cell including transformed lymphoma and T-/NK-cell excluding primary cutaneous disease.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dose Level 1 (Flavopiridol 30 mg/m2 + 30 mg/m2)</title>
          <description>Patients receive flavopiridol IV over 4Â½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="P2">
          <title>Dose Level 2 (Flavopiridol 30 mg/m2 + 50 mg/m2)</title>
          <description>Patients receive flavopiridol IV over 4Â½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="P3">
          <title>Dose Level 3 (Flavopiridol 50 mg/m2 + 50 mg/m2)</title>
          <description>Patients receive flavopiridol IV over 4Â½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Patients Evaluable for Toxicity</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Alvocidib)</title>
          <description>PHASE I: Patients receive flavopiridol IV over 4Â½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of flavopiridol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
PHASE II: Patients receive flavopiridol* as in phase I at the MTD determined in phase I.&#xD;
alvocidib: Given IV</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" lower_limit="34" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>patients</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eastern Cooperative Oncology Group (ECOG) Performance status</title>
          <units>patients</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0 (Fully active)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 (Restricted in physically strenuous activity)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 (Ambulatory capable of all selfcare)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diagnosis</title>
          <units>patients</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Indolent B-cell</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>intermediate grade B-NHL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mantle cell lymphoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T/NK cell NHL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Disease-specific Dose-limiting Toxicity and Maximum Tolerated Dose of Flavopiridol Graded According to the CTCAE (Common Toxicity Criteria for Adverse Effects) Version 4.0 (Phase I)</title>
        <description>Dose limiting toxicity (DLT) for an individual disease group is defined as 1) any grade 3-4 non-hematologic toxicity (except leukopenia or neutropenia) that does not resolve or decrease to grade 1-2 within 2 weeks, or 2) any grade 4 hematologic toxicity that causes more than a 1 week delay in administration of therapy.</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 1 (Flavopiridol 30 mg/m2 + 30 mg/m2)</title>
            <description>PHASE I: Patients receive flavopiridol IV over 4Â½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
PHASE II: Patients receive flavopiridol* as in phase I at the MTD determined in phase I.</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 2 (Flavopiridol 30 mg/m2 + 50 mg/m2)</title>
            <description>PHASE I: Patients receive flavopiridol IV over 4Â½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
PHASE II: Patients receive flavopiridol* as in phase I at the MTD determined in phase I.</description>
          </group>
          <group group_id="O3">
            <title>Dose Level 3 (Flavopiridol 50 mg/m2 + 50 mg/m2)</title>
            <description>PHASE I: Patients receive flavopiridol IV over 4Â½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
PHASE II: Patients receive flavopiridol* as in phase I at the MTD determined in phase I.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-specific Dose-limiting Toxicity and Maximum Tolerated Dose of Flavopiridol Graded According to the CTCAE (Common Toxicity Criteria for Adverse Effects) Version 4.0 (Phase I)</title>
          <description>Dose limiting toxicity (DLT) for an individual disease group is defined as 1) any grade 3-4 non-hematologic toxicity (except leukopenia or neutropenia) that does not resolve or decrease to grade 1-2 within 2 weeks, or 2) any grade 4 hematologic toxicity that causes more than a 1 week delay in administration of therapy.</description>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose (MTD)</title>
        <description>The maximum tolerated dose (MTD) is defined as that dose level beneath the dose at which 2 or more of 6 patients experience DLT.</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 1 (30+30)</title>
            <description>PHASE I: Patients receive flavopiridol IV over 4Â½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
PHASE II: Patients receive flavopiridol* as in phase I at the MTD determined in phase I.&#xD;
alvocidib: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Level 2 (30+50)</title>
            <description>PHASE I: Patients receive flavopiridol IV over 4Â½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
PHASE II: Patients receive flavopiridol* as in phase I at the MTD determined in phase I.</description>
          </group>
          <group group_id="O3">
            <title>Level 3 (50+50)</title>
            <description>PHASE I: Patients receive flavopiridol IV over 4Â½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
PHASE II: Patients receive flavopiridol* as in phase I at the MTD determined in phase I.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose (MTD)</title>
          <description>The maximum tolerated dose (MTD) is defined as that dose level beneath the dose at which 2 or more of 6 patients experience DLT.</description>
          <units>mg/m2</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="80"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Complete and Partial Response Rate (Phase II)</title>
        <description>Patients were assessed for clinical response after two , four and six cycle with laboratory studies, physical exam, and CT scans. Response was evaluated using the modified NCI-sponsored Working Group Lymphoma Response Criteria.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Includes patients enrolled with Indolent B-cell NHL, Intermediate Grade B NHL, Mantle cell NHL and T/NK-cell NHL</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 1 (Flavopiridol 30 mg/m2 + 30 mg/m2)</title>
            <description>Patients receive flavopiridol IV over 4Â½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of flavopiridol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 2 (Flavopiridol 30 mg/m2 + 50 mg/m2)</title>
            <description>Patients receive flavopiridol IV over 4Â½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of flavopiridol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Dose Level 3 Dose (Flavopiridol 50 mg/m2 + 50 mg/m2)</title>
            <description>Patients receive flavopiridol IV over 4Â½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of flavopiridol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Complete and Partial Response Rate (Phase II)</title>
          <description>Patients were assessed for clinical response after two , four and six cycle with laboratory studies, physical exam, and CT scans. Response was evaluated using the modified NCI-sponsored Working Group Lymphoma Response Criteria.</description>
          <population>Includes patients enrolled with Indolent B-cell NHL, Intermediate Grade B NHL, Mantle cell NHL and T/NK-cell NHL</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Qualitative and Quantitative Toxicities in Regard to Organ Specificity</title>
        <description>The NCI Common Toxicity Criteria for Adverse Events (version 3.0) were used to define and grade toxicity for patients.</description>
        <time_frame>Up to 30 days after completion of study treatment</time_frame>
        <population>Grade 3 and 4 toxicities.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Levels 1, 2, 3</title>
            <description>Dose Level 1 (30 mg/m2 + 30 mg/m2), Dose Level 2 (30 mg/m2 + 50 mg/m2), Dose Level 3 (50 mg/m2 + 50 mg/m2)&#xD;
PHASE I: Patients receive flavopiridol IV over 4Â½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
PHASE II: Patients receive flavopiridol* as in phase I at the MTD determined in phase I.&#xD;
alvocidib: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Qualitative and Quantitative Toxicities in Regard to Organ Specificity</title>
          <description>The NCI Common Toxicity Criteria for Adverse Events (version 3.0) were used to define and grade toxicity for patients.</description>
          <population>Grade 3 and 4 toxicities.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Leukopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutropenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lymphoid/Plasma Cell Malignancies</title>
        <description>Identify subsets, based on levels of response (PR and SD), of lymphoid / plasma cell malignancies that are suitable for larger phase II studies designed to further evaluate the efficacy and toxicity of flavopiridol.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Response indicated for Indolent B-cell NHL, Mantle cell NHL and T-cell NHL</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Patients diagnosed with Indolent B-cell NHL</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>Patients diagnosed with Mantle Cell NHL</description>
          </group>
          <group group_id="O3">
            <title>Cohort 4</title>
            <description>Patients diagnosed with T Cell NHL</description>
          </group>
        </group_list>
        <measure>
          <title>Lymphoid/Plasma Cell Malignancies</title>
          <description>Identify subsets, based on levels of response (PR and SD), of lymphoid / plasma cell malignancies that are suitable for larger phase II studies designed to further evaluate the efficacy and toxicity of flavopiridol.</description>
          <population>Response indicated for Indolent B-cell NHL, Mantle cell NHL and T-cell NHL</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (Area Under the Curve; AUC) of Flavopiridol</title>
        <description>Whole blood samples were collected for pharmacokinetics analysis during the first (Day 1) and fourth (Day 22) treatments during cycle 1. Samples were collected on both occasions prior to dosing and at 0.5, 1, 3, 4.5, 6, 8 and 24 hour after the start of the bolus infusion.</description>
        <time_frame>0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours post-dose on Days 1 and 22 of Cycle 1</time_frame>
        <population>total of 71 PK (Pharmacokinetic) profiles comprising 484 plasma concentration were determined for 45 of 46 patients following treatment</population>
        <group_list>
          <group group_id="O1">
            <title>All Dose Levels of Alvocidib</title>
            <description>PHASE I: Patients receive flavopiridol IV over 4Â½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
PHASE II: Patients receive flavopiridol* as in phase I at the MTD determined in phase I.&#xD;
alvocidib: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (Area Under the Curve; AUC) of Flavopiridol</title>
          <description>Whole blood samples were collected for pharmacokinetics analysis during the first (Day 1) and fourth (Day 22) treatments during cycle 1. Samples were collected on both occasions prior to dosing and at 0.5, 1, 3, 4.5, 6, 8 and 24 hour after the start of the bolus infusion.</description>
          <population>total of 71 PK (Pharmacokinetic) profiles comprising 484 plasma concentration were determined for 45 of 46 patients following treatment</population>
          <units>hrÃÎ¼M</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.404" spread="5.923"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.949" spread="5.109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Reporting Acute Infusion Toxicity (e.g., Fever, Hypotension, Tumor Pain, and Dyspnea)</title>
        <time_frame>Up to 30 days after completion of study treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Dose Levels of Alvocidib</title>
            <description>PHASE I: Patients receive flavopiridol IV over 4Â½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of flavopiridol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
PHASE II: Patients receive flavopiridol* as in phase I at the MTD determined in phase I.&#xD;
alvocidib: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Reporting Acute Infusion Toxicity (e.g., Fever, Hypotension, Tumor Pain, and Dyspnea)</title>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Induced Response in Patients Independent of p53 Mutational Status</title>
        <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Data not available due to studies were not conducted by collaborating laboratory Investigator</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 1 (Flavopiridol 30 mg/m2 + 30 mg/m2)</title>
            <description>PHASE I: Patients receive flavopiridol IV over 4Â½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
PHASE II: Patients receive flavopiridol* as in phase I at the MTD determined in phase I.</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 2 (Flavopiridol 30 mg/m2 + 50 mg/m2)</title>
            <description>PHASE I: Patients receive flavopiridol IV over 4Â½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
PHASE II: Patients receive flavopiridol* as in phase I at the MTD determined in phase I.</description>
          </group>
          <group group_id="O3">
            <title>Dose Level 3 (Flavopiridol 50 mg/m2 + 50 mg/m2)</title>
            <description>PHASE I: Patients receive flavopiridol IV over 4Â½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
PHASE II: Patients receive flavopiridol* as in phase I at the MTD determined in phase I.</description>
          </group>
        </group_list>
        <measure>
          <title>Induced Response in Patients Independent of p53 Mutational Status</title>
          <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
          <population>Data not available due to studies were not conducted by collaborating laboratory Investigator</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamic Effects of Flavopiridol on Normal Peripheral Blood Mononuclear Cells (PBMCs).</title>
        <description>The correlation of the pharmacodynamic effects of flavopiridol on normal peripheral blood mononuclear cells (PBMCs)</description>
        <time_frame>Day 1</time_frame>
        <population>Data not available due to studies were not conducted by collaborating laboratory Investigator</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 1 (Flavopiridol 30 mg/m2 + 30 mg/m2)</title>
            <description>Patients receive flavopiridol IV over 4Â½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 2 (Flavopiridol 30 mg/m2 + 50 mg/m2)</title>
            <description>Patients receive flavopiridol IV over 4Â½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Dose Level 3 (Flavopiridol 50 mg/m2 + 50 mg/m2)</title>
            <description>Patients receive flavopiridol IV over 4Â½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamic Effects of Flavopiridol on Normal Peripheral Blood Mononuclear Cells (PBMCs).</title>
          <description>The correlation of the pharmacodynamic effects of flavopiridol on normal peripheral blood mononuclear cells (PBMCs)</description>
          <population>Data not available due to studies were not conducted by collaborating laboratory Investigator</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (Cmax) of Flavopiridol</title>
        <description>Whole blood samples were collected for pharmacokinetics analysis during the first (Day 1) and fourth (Day 22) treatments during cycle 1. Samples were collected on both occasions prior to dosing and at 0.5, 1, 3, 4.5, 6, 8 and 24 hour after the start of the bolus infusion.</description>
        <time_frame>0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours post-dose on Days 1 and 22 of Cycle 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Dose Levels of Alvocidib</title>
            <description>PHASE I: Patients receive flavopiridol IV over 4Â½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
PHASE II: Patients receive flavopiridol* as in phase I at the MTD determined in phase I.&#xD;
alvocidib: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (Cmax) of Flavopiridol</title>
          <description>Whole blood samples were collected for pharmacokinetics analysis during the first (Day 1) and fourth (Day 22) treatments during cycle 1. Samples were collected on both occasions prior to dosing and at 0.5, 1, 3, 4.5, 6, 8 and 24 hour after the start of the bolus infusion.</description>
          <units>Î¼M</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.954" spread="0.886"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.071" spread="0.820"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Patients were assessed for clinical response after two, four and six cycles with laboratory studies, physical exam, and CT scans.</time_frame>
      <desc>NCI Common Toxicity Criteria for Adverse Events (version 3.0) was used to define and grade toxicity.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Alvocidib)</title>
          <description>PHASE I: Patients receive flavopiridol IV over 4Â½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of flavopiridol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
PHASE II: Patients receive flavopiridol* as in phase I at the MTD determined in phase I.&#xD;
alvocidib: Given IV</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE version 3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia fever</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Cytokine Release Syndrome</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="34" subjects_affected="34" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Increased ALT/AST</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Tumor Lysis Syndrome</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jeffrey Jones, MD</name_or_title>
      <organization>The Ohio State University Comprehensive Cancer Center</organization>
      <phone>614-293-3507</phone>
      <email>Jeffrey.Jones@osumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

